Business & Industry

Merck KGaA to Acquire Bio-Techne for $11.3 Billion to Bolster Life Science Division

Yuvraj — Fri, 26 Jun 2026 07:32:09 +0000

The German pharmaceutical group Merck KGaA announced that it has entered into a definitive agreement to purchase the United States-based biotechnology firm Bio-Techne for $11.3 billion. This transaction represents the largest deal for the Darmstadt-based organization in more than a decade, as it seeks to significantly enhance its global life sciences business. Under the terms […]

The post Merck KGaA to Acquire Bio-Techne for $11.3 Billion to Bolster Life Science Division first appeared on World Pharma Today.

Novartis and Antares Therapeutics Form Strategic Partnership for Cancer Drug Development

Yuvraj — Fri, 26 Jun 2026 07:23:30 +0000

Novartis has finalized a significant collaboration agreement with Antares Therapeutics to advance the discovery and development of small molecule therapies for various cancers. The deal, which could reach a total value of $1.9 billion, focuses on addressing oncology targets that have historically been categorized as undruggable. Under the terms of the agreement, Novartis will provide […]

The post Novartis and Antares Therapeutics Form Strategic Partnership for Cancer Drug Development first appeared on World Pharma Today.

Abu Dhabi and MSD Partner to Enhance Healthcare Access via New Logistics Hub

Yuvraj — Fri, 26 Jun 2026 05:12:11 +0000

The Department of Health – Abu Dhabi (DoH) has announced a strategic collaboration with MSD to evaluate the feasibility of establishing an Abu Dhabi logistics hub. Located within the Health, Endurance, Longevity, and Medicine (HELM) Cluster, this planned facility is designed to streamline the distribution of a comprehensive portfolio of pharmaceutical products across diverse regional […]

The post Abu Dhabi and MSD Partner to Enhance Healthcare Access via New Logistics Hub first appeared on World Pharma Today.

Bayer and Iambic Collaboration Expands AI Drug Discovery Efforts

Yuvraj — Thu, 25 Jun 2026 05:47:49 +0000

Bayer has strengthened its pharmaceutical and ophthalmology portfolio through two separate transactions, completing the acquisition of Perfuse Therapeutics while also entering a collaboration agreement with Iambic Therapeutics. The moves provide Bayer with full ownership of Perfuse’s lead asset, PER-001, and expand its access to advanced artificial intelligence technologies aimed at accelerating drug development. The acquisition […]

The post Bayer and Iambic Collaboration Expands AI Drug Discovery Efforts first appeared on World Pharma Today.

Sanofi Partners with Pangaea for AI-Driven AATD Detection

Yuvraj — Wed, 24 Jun 2026 13:41:26 +0000

Pangaea Data (Pangaea), a provider of a guideline-configured AI platform designed to help close care gaps and improve the identification of untreated and under-treated patients with difficult-to-diagnose conditions, has entered into a collaboration agreement with Sanofi. Under the arrangement, Pangaea’s technology will be deployed across a group of large health systems in the United States […]

The post Sanofi Partners with Pangaea for AI-Driven AATD Detection first appeared on World Pharma Today.

Lilly and BioArctic Partner on BrainTransporter Technology

Yuvraj — Wed, 24 Jun 2026 13:06:58 +0000

Eli Lilly and Company has entered into a research and collaboration agreement with Swedish biopharmaceutical company BioArctic to advance a potential treatment for neurodegenerative diseases. Under the arrangement, the companies will combine BioArctic’s BrainTransporter Technology with an undisclosed Lilly drug candidate. BioArctic will receive an upfront payment of $30m and may earn up to $770m […]

The post Lilly and BioArctic Partner on BrainTransporter Technology first appeared on World Pharma Today.

AbbVie Acquires Apogee in $10.9 Billion Healthcare Deal

Yuvraj — Wed, 24 Jun 2026 12:58:04 +0000

In a significant expansion of its research and development capabilities, a definitive agreement has been reached where AbbVie acquires Apogee Therapeutics for $10.9 billion. This strategic transaction is centered around the addition of zumilokibart, a highly anticipated IL-13 antibody, to the acquiring company’s expanding pipeline. By bringing this advanced asset in-house, the organization aims to […]

The post AbbVie Acquires Apogee in $10.9 Billion Healthcare Deal first appeared on World Pharma Today.

Insilico Medicine Advances ISM8969 Into Phase 1 Trial as Brain-Penetrant NLRP3 Inhibitor for Neuroinflammation

Yuvraj — Fri, 19 Jun 2026 07:39:02 +0000

Insilico Medicine has reached a significant clinical milestone with the completion of first-in-human dosing of ISM8969 in a Phase 1 study. Conducted in collaboration with Hygtia Therapeutics, the ISM8969 Phase 1 trial marks the transition of this oral, brain-penetrant NLRP3 inflammasome inhibitor from preclinical development into human evaluation. The compound is designed to address chronic […]

The post Insilico Medicine Advances ISM8969 Into Phase 1 Trial as Brain-Penetrant NLRP3 Inhibitor for Neuroinflammation first appeared on World Pharma Today.

Moderna Commercial Expansion Accelerates Vaccine Launches

Yuvraj — Thu, 18 Jun 2026 10:26:16 +0000

Moderna is strengthening its commercial leadership and operational structure as it prepares for a series of anticipated vaccine launches over the next several years. The company expects potential introductions of its mRNA-based seasonal flu vaccine, combined flu/COVID-19 vaccine, and norovirus vaccine between 2027 and 2028. As part of this effort, Moderna has appointed Esther Banque, […]

The post Moderna Commercial Expansion Accelerates Vaccine Launches first appeared on World Pharma Today.

Jazz AbCellera Alliance Targets Next-Generation Cancer Drugs

Yuvraj — Thu, 18 Jun 2026 09:46:59 +0000

Jazz Pharma has entered into a major collaboration with AbCellera focused on advancing cancer immunotherapy programmes, signing an agreement that could ultimately exceed $4 billion in value. Under the arrangement, the companies will work on up to five multispecific antibody-based T-cell engager (TCE) candidates targeting gastrointestinal cancers and other solid tumours. The deal includes an […]

The post Jazz AbCellera Alliance Targets Next-Generation Cancer Drugs first appeared on World Pharma Today.